Browsing Tag
Merck KGaA
8 posts
Why Merck KGaA is spending $11.3bn on Bio-Techne instead of another drug pipeline
Merck KGaA plans to acquire Bio-Techne for $11.3 billion. Read why laboratory tools, recurring revenue and debt-funded growth could reshape its strategy.
Abbisko Therapeutics’ pimicotinib clears FDA filing hurdle: Why this matters for rare tumor strategy and global biotech credibility
Abbisko Therapeutics clears a key FDA hurdle for pimicotinib. Find out why this TGCT filing could reshape rare tumor strategy and global biotech credibility.
Merck KGaA to acquire SpringWorks Therapeutics in $3.9bn rare tumor expansion
Find out how Merck KGaA, Darmstadt, Germany’s $3.9 billion SpringWorks acquisition is reshaping rare tumor treatment and global healthcare leadership.
Recursion Pharmaceuticals’ stock plunges 7% after shock Q4 loss – What went wrong?
Recursion Pharmaceuticals, a clinical-stage biotechnology company leveraging artificial intelligence for drug discovery, reported a significantly wider loss for…
Biotech breakthrough: Mersana Therapeutics stock soars 23% after blowing past Q3 expectations
Mersana Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) for cancer treatment, saw its…
Gamma Biosciences to sell Mirus Bio to Merck KGaA for $600m in key biotech deal
Merck KGaA, Darmstadt, Germany (XTRA:MRK), a leading global science and technology company, has agreed to acquire Mirus Bio…
MilliporeSigma invests over €300m in new South Korean bioprocessing center
MilliporeSigma, the Life Science business of Merck KGaA, Darmstadt, Germany, in the United States and Canada, has earmarked…
EMD Serono facility expansion in Massachusetts set to advance immuno-oncology research
German pharmaceutical giant Merck KGaA has announced a significant investment of $70 million to expand its EMD Serono…